	10D-CT	BQT (10	D, 14D)		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events Tot	al Events	Total	Weight	M-H. Random, 95% C	M-H. Random, 95% Cl	ABCDEFG
Ayse Kefeli(2016)	113 1	30 114	130	23.9%	0.99 [0.90, 1.09]	•	
BASYIGIT(2016)	98 12	27 46	71	13.0%	1.19 [0.98, 1.45]	-	
Fracesco (2018)	60	3 52	61	20.7%	1.12 [0.99, 1.26]	•	
Gungor (2015)	72 1	00 62	100	12.9%	1.16 [0.95, 1.41]	-	******
Liou(2016)	464 54	10 488	540	29.5%	0.95 [0.91, 0.99]	•	
Total (95% CI)	90	0	902	100.0%	1.05 [0.96, 1.15]		
Total events	807	762					
Heterogeneity: Tau ² = 0.01; Chi ² = 14.09, df = 4 (P = 0.007); l ² = 72%							100
Test for overall effect: $7 = 1.03 (P = 0.31)$						0.01 0.1 1 10 1 BQT (10D, 14D) 10D-CT	100

Risk of bias legend

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)


(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias



Risk of bias legend

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Supplementary Fig. 6. Comparison between 10-day concomitant therapy and 10-/14-day bismuth quadruple therapy. (A) Intention-to-treat analysis. (B) Per protocol analysis. CT, concomitant therapy; BQT, bismuth quadruple therapy; M-H, Mantel-Haenszel test.

 (\mathbf{B})

A